Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Paulzen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Der Nervenarzt|April 18, 2014
[Schizophrenia and other psychotic disorders in DSM-5: summary of the changes compared to DSM-IV]M Paulzen, F Schneider
Pharmacopsychiatry|October 8, 2011
Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patientsM Paulzen, A Finkelmeyer, M Grözinger
Der Nervenarzt|September 8, 2012
[Basic principles of therapy with neuropsychotropic drugs]G Gründer, T Veselinović, M Paulzen
Der Nervenarzt|June 28, 2014
[Antidepressive agents and suicidal tendencies]G Gründer, T Veselinović, M Paulzen
Der Nervenarzt|June 12, 2025
[Galactorrhea with euprolactinemia under SSRI treatment]J Schreiber, R Demann, M Paulzen, et al.
Der Nervenarzt|October 24, 2013
[Integrated care for depressive disorders]M Paulzen, A Müller, T Akkus, et al.
Pharmacopsychiatry|October 1, 2011
Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imagingG Gründer, C Hiemke, M Paulzen, et al.
Pharmacopsychiatry|February 2, 2018
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017C Hiemke, N Bergemann, H W Clement, et al.
Pharmacopsychiatry|September 15, 2017
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017C Hiemke, N Bergemann, H W Clement, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Der Nervenarzt|April 18, 2014
[Schizophrenia and other psychotic disorders in DSM-5: summary of the changes compared to DSM-IV]M Paulzen, F Schneider
Pharmacopsychiatry|October 8, 2011
Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patientsM Paulzen, A Finkelmeyer, M Grözinger
Der Nervenarzt|September 8, 2012
[Basic principles of therapy with neuropsychotropic drugs]G Gründer, T Veselinović, M Paulzen
Der Nervenarzt|June 28, 2014
[Antidepressive agents and suicidal tendencies]G Gründer, T Veselinović, M Paulzen
Der Nervenarzt|June 12, 2025
[Galactorrhea with euprolactinemia under SSRI treatment]J Schreiber, R Demann, M Paulzen, et al.
Der Nervenarzt|October 24, 2013
[Integrated care for depressive disorders]M Paulzen, A Müller, T Akkus, et al.
Pharmacopsychiatry|October 1, 2011
Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imagingG Gründer, C Hiemke, M Paulzen, et al.
Pharmacopsychiatry|February 2, 2018
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017C Hiemke, N Bergemann, H W Clement, et al.
Pharmacopsychiatry|September 15, 2017
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017C Hiemke, N Bergemann, H W Clement, et al.
Pageof 1